Renal Pharmacology · Module 4 of 5

Renal Transplant Immunosuppression

Induction, maintenance, and rejection treatment · Calcineurin inhibitors · Antiproliferatives · mTOR inhibitors · Rejection classification

Transplant immunosuppression operates across three temporal phases. Induction (days to weeks post-transplant): highest alloimmune risk; goal is rapid deep T-cell suppression. Standard-risk recipients → basiliximab (anti-CD25 mAb; two doses day 0 and day 4; blocks IL-2R-driven T-cell clonal expansion; well tolerated). High-risk or sensitized recipients → antithymocyte globulin (rabbit, polyclonal; T-cell depletion via complement lysis and ADCC; risks: infusion reactions, profound lymphopenia, CMV, PTLD). Maintenance (lifelong): standard triple-drug regimen — calcineurin inhibitor (tacrolimus preferred) + antiproliferative (mycophenolate mofetil preferred) + low-dose corticosteroid (prednisone 5–10 mg/day). Rejection treatment: T-cell mediated → pulse methylprednisolone 500 mg IV ×3 days; steroid-resistant → antithymocyte globulin. Antibody-mediated → plasmapheresis + IVIG + rituximab (anti-CD20).
Calcineurin inhibitors: tacrolimus binds FKBP12 → tacrolimus-FKBP12 complex inhibits calcineurin (phosphatase) → NFAT cannot be dephosphorylated → cannot translocate to nucleus → IL-2 gene transcription blocked → T-cell activation arrested. Cyclosporine binds cyclophilin → cyclosporine-cyclophilin complex inhibits the same calcineurin target. Tacrolimus is 10–100× more potent on a molar basis and is now the standard. Both are CYP3A4 + P-gp substrates → massive drug interaction network; TDM with trough levels is mandatory. Nephrotoxicity: acute (afferent arteriolar vasoconstriction via TXA2 and endothelin → ↓ RBF and GFR; dose-dependent, reversible); chronic (interstitial fibrosis + tubular atrophy from sustained ischemia → irreversible; primary driver of CNI minimization). Divergent AEs: cyclosporine → gingival hyperplasia, hirsutism, more hyperlipidemia. Tacrolimus → PTDM (β-cell toxicity + insulin resistance), neurotoxicity (tremor, PRES).
Antiproliferative agents: mycophenolate mofetil (prodrug → mycophenolic acid) uncompetitively inhibits IMPDH → blocks de novo guanosine synthesis → T and B cells cannot proliferate (lymphocytes rely almost exclusively on de novo purine synthesis). Superior to azathioprine in randomized trials — now the preferred antiproliferative. AEs: GI (nausea/vomiting/diarrhea 20–30%; dose-limiting; enteric-coated formulation may reduce upper GI symptoms); leukopenia/thrombocytopenia at higher doses; teratogenic — absolutely contraindicated in pregnancy. Azathioprine: thiopurine prodrug → 6-MP → thioguanine nucleotides → DNA strand breaks in lymphocytes. TPMT deficiency (~0.3% prevalence): accumulate toxic TGN → severe myelosuppression at standard doses; TPMT genotyping before initiation. Critical interaction: allopurinol inhibits XO → ↑ 6-MP → ↑ TGN levels → 75% azathioprine dose reduction required, or switch to MMF.
mTOR inhibitors (sirolimus, everolimus): bind FKBP12 (same as tacrolimus) but do NOT inhibit calcineurin; instead, drug-FKBP12 complex inhibits mTORC1 → blocks cytokine-driven T-cell proliferation at G1→S phase transition (calcineurin-independent). Role: CNI minimization when established CNI nephrotoxicity — mTOR inhibitors are not nephrotoxic via vasoconstriction. AEs: wound healing impairment (contraindicated <3 months post-transplant); mouth ulcers (aphthous; dose-limiting); pneumonitis (non-infectious interstitial lung inflammation — discontinue drug); dyslipidemia (hypertriglyceridemia in majority); peripheral edema; proteinuria. Secondary role: post-transplant skin malignancies (mTOR inhibition has anti-tumor benefit).
Rejection classification: T-cell mediated (TCMR) — lymphocytic tubulitis + interstitial inflammation ± endotheliitis on biopsy; rising creatinine, ↓ urine output; treatment: pulse methylprednisolone 500 mg IV ×3 days; steroid-resistant → antithymocyte globulin. Antibody-mediated (AMR) — pre-formed or de novo donor-specific antibodies (DSAs) against donor HLA → complement activation → endothelial injury → peritubular capillary inflammation + C4d deposition on biopsy; treatment: plasmapheresis (removes DSAs) + IVIG (modulates residual antibody injury) + rituximab (depletes B cells + plasma cell precursors); worse prognosis than TCMR → leading cause of late graft loss. Drug interaction rule: recheck tacrolimus/cyclosporine trough levels after starting or stopping azoles (↑ 2–5×), macrolides (↑), diltiazem/verapamil (↑), rifampin (↓ dramatically → rejection risk), phenytoin/carbamazepine (↓), St. John's Wort (↓).

ADCC = antibody-dependent cellular cytotoxicity · AMR = antibody-mediated rejection · ATG = antithymocyte globulin · CMV = cytomegalovirus · CNI = calcineurin inhibitor · DSA = donor-specific antibody · FKBP12 = FK-binding protein 12 · HLA = human leukocyte antigen · IL-2 = interleukin-2 · IMPDH = inosine monophosphate dehydrogenase · mAb = monoclonal antibody · MMF = mycophenolate mofetil · mTOR = mechanistic target of rapamycin · NFAT = nuclear factor of activated T cells · PRES = posterior reversible encephalopathy syndrome · PTDM = post-transplant diabetes mellitus · PTLD = post-transplant lymphoproliferative disorder · TCMR = T-cell mediated rejection · TDM = therapeutic drug monitoring · TPMT = thiopurine methyltransferase · TXA2 = thromboxane A2 · XO = xanthine oxidase · 6-MP = 6-mercaptopurine

Three Temporal Phases of Transplant Immunosuppression

Phase 1 — Days to Weeks

Induction

Highest alloimmune risk — first encounter with donor antigens
Goal: rapid deep T-cell suppression before maintenance takes full effect
Standard risk: basiliximab (anti-CD25; two IV doses; well tolerated)
High risk / sensitized: antithymocyte globulin (polyclonal T-cell depletion; infusion reactions; lymphopenia; CMV; PTLD)

Phase 2 — Lifelong

Maintenance — Triple Therapy

Complementary immunosuppression at three distinct T-cell activation points
Calcineurin inhibitor: tacrolimus (preferred) — blocks IL-2 transcription
Antiproliferative: mycophenolate mofetil (preferred) — blocks lymphocyte purine synthesis
Corticosteroid: prednisone 5–10 mg/day — broad NF-κB-mediated cytokine suppression

Phase 3 — As Needed

Rejection Treatment

TCMR: pulse methylprednisolone 500 mg IV daily ×3 days
Steroid-resistant TCMR: antithymocyte globulin (depletes alloreactive T cells)
AMR: plasmapheresis (remove DSAs) + IVIG (modulate injury) + rituximab (anti-CD20 B-cell depletion)
AMR: worse prognosis; leading cause of late graft loss

Calcineurin Inhibitors — Mechanism and Adverse Effects

	Tacrolimus	Cyclosporine
Immunophilin	Binds FKBP12	Binds cyclophilin
Downstream target	Both form drug-immunophilin complexes that inhibit calcineurin → NFAT cannot enter nucleus → IL-2 gene transcription blocked
Potency	10–100× more potent on molar basis — now standard of care	Less potent; largely superseded by tacrolimus
Distinct AEs	PTDM (β-cell toxicity + insulin resistance); neurotoxicity (tremor, PRES)	Gingival hyperplasia; hirsutism; more hyperlipidemia
Shared AEs	Nephrotoxicity (afferent arteriolar vasoconstriction → reversible acute; interstitial fibrosis → irreversible chronic); hypertension; hyperuricemia; CYP3A4 + P-gp substrate — TDM mandatory

Antiproliferative Agents and mTOR Inhibitors

Preferred Antiproliferative

Mycophenolate Mofetil

Prodrug → mycophenolic acid; uncompetitively inhibits IMPDH → blocks de novo guanosine synthesis
Lymphocytes rely almost exclusively on de novo purine synthesis → selective suppression
Superior rejection prevention versus azathioprine — now preferred antiproliferative
GI AEs (nausea/vomiting/diarrhea) in 20–30%; enteric-coated form may help
Leukopenia/thrombocytopenia at higher doses
Teratogenic — absolutely contraindicated in pregnancy; mandatory contraception

Alternative Antiproliferative

Azathioprine

Thiopurine prodrug → 6-MP → thioguanine nucleotides → DNA strand breaks in lymphocytes
TPMT deficiency (~0.3%): accumulate toxic TGN → severe myelosuppression at standard doses; genotype before initiating
Allopurinol interaction: inhibits XO → ↑ 6-MP → ↑ TGN; reduce azathioprine by 75% or switch to MMF
Largely superseded by MMF in transplant; retained in IBD and autoimmune disease

mTOR Inhibitors

Sirolimus / Everolimus

Bind FKBP12 (same as tacrolimus) but inhibit mTORC1 — not calcineurin → calcineurin-independent T-cell proliferation block at G1→S
Not nephrotoxic via vasoconstriction → role in CNI minimization
Wound healing impairment — start no earlier than 3 months post-transplant
Mouth ulcers (aphthous); pneumonitis (discontinue); hypertriglyceridemia; proteinuria; edema
Post-transplant skin malignancies: anti-tumor benefit from mTOR inhibition

Rejection Classification and Treatment

T-Cell Mediated Rejection (TCMR)

Lymphocytic Tubulitis

Histology: lymphocytic tubulitis + interstitial inflammation ± endotheliitis (arteritis in severe cases)
Clinical: rising creatinine, ↓ urine output, graft tenderness
First-line: methylprednisolone 500 mg IV daily ×3 days
Most TCMR responds to pulse steroids
Steroid-resistant (no improvement 3–5 days): antithymocyte globulin — depletes alloreactive T-cell population

Antibody-Mediated Rejection (AMR)

Donor-Specific Antibodies

Pre-formed or de novo DSAs against donor HLA on graft endothelium → complement → endothelial injury
Histology: peritubular capillary inflammation + C4d deposition
Plasmapheresis: removes circulating DSAs
IVIG: modulates residual antibody-mediated injury
Rituximab (anti-CD20): depletes B cells and plasma cell precursors
More treatment-resistant than TCMR; leading cause of late graft loss — substantially worse prognosis

Calcineurin Inhibitor Drug Interactions — Recheck Trough After Every Change

Tacrolimus and cyclosporine have narrow therapeutic indices and are substrates of both CYP3A4 and P-glycoprotein. Drug interactions can cause 2 to 5-fold changes in blood levels. Trough levels must be rechecked after starting or stopping any of the following agents. Inhibitors (increase CNI levels → toxicity risk): azole antifungals (fluconazole, voriconazole, itraconazole), macrolide antibiotics (erythromycin, clarithromycin), diltiazem, verapamil. Inducers (decrease CNI levels → rejection risk): rifampin (most dangerous — can cause dramatic level drops within days), phenytoin, carbamazepine, phenobarbital, St. John's Wort.

Failure to recheck CNI trough levels after a regimen change is the most common preventable cause of calcineurin inhibitor toxicity or acute rejection in the outpatient transplant setting.

Suggested References

Author / Source	Title	Publication
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed.	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill, 2023
KDIGO Transplant Work Group	KDIGO clinical practice guideline for the care of kidney transplant recipients	Am J Transplant. 2009;9(Suppl 3):S1–S155
Webster AC, Woodroffe RC, Taylor RS, et al	Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients	Cochrane Database Syst Rev. 2005;4:CD003961
Halloran PF	Immunosuppressive drugs for kidney transplantation	N Engl J Med. 2004;351(26):2715–2729
Sollinger HW	Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients	Transplantation. 1995;60(3):225–232
Lennard L	The clinical pharmacology of 6-mercaptopurine	Eur J Clin Pharmacol. 1992;43(4):329–339
Ekberg H, Tedesco-Silva H, Demirbas A, et al	Reduced exposure to calcineurin inhibitors in renal transplantation	N Engl J Med. 2007;357(25):2562–2575
Solez K, Colvin RB, Racusen LC, et al	Banff 07 classification of renal allograft pathology: updates and future directions	Am J Transplant. 2008;8(4):753–760
Nankivell BJ, Alexander SI	Rejection of the kidney allograft	N Engl J Med. 2010;363(15):1451–1462
Lefaucheur C, Loupy A, Hill GS, et al	Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation	J Am Soc Nephrol. 2010;21(8):1398–1406
Matas AJ, Smith JM, Skeans MA, et al	OPTN/SRTR 2012 annual data report: kidney	Am J Transplant. 2014;14(Suppl 1):11–44